A 39-year-old male underwent a nonmyeloablative stem cell transplant (NMAPBPCT) from his HLA-matched sister for recurrent anaplastic large cell lymphoma in CR-2, receiving fludarabine, cyclophosphamide, and rabbit antithymocyte globulin for the preparative therapy. The patient was readmitted on day+33 for persistent culturenegative fevers. He rapidly developed marked elevations of alkaline phosphatase and bilirubin. Liver biopsy showed a periportal infiltrate of large immunoblastic appearing cells. The tumor cells did not stain for CD3/CD20/CD30 and alk protein, but did stain for CD79a/LCA and CD43. In situ hybridization for Epstein-Barr virus (EBV) RNA (EBER 1) was strongly positive in the periportal infiltrating lymphocytes. Fluorescence in situ hybridization (FISH) studies revealed female (XX) cells in the tumor cells and male (XY) in the surrounding hepatic parenchymal cells. The patient developed severe lactic acidosis, oliguric renal failure and expired on day+44. Both donor and patient had positive IgG serologies for EBV VCA and EBNA pretransplant. The donor also had a positive IgM titer for EBV VCA in the pretransplant specimen. The LPD may have been related to the intense immunosuppression of the preparative therapy and the presence of recent EBV infection in the donor.
EBV; post-transplant lymphoproliferative disorder; non-myeloablative transplant Lymphoproliferative disorders (LPDs) occurring after allogeneic stem cell transplant are usually associated with Epstein-Barr virus (EBV) transformation of donor B lymphocytes. 1 LPD post allogeneic stem cell transplant most often occurs in recipients of T-cell-depleted grafts, or in recipients of non-T-cell depleted, but mismatched-related or -unrelated grafts or in recipients of unmodified stem cell grafts who receive antithymocyte globulin or anti-CD3 monoclonal antibody for treatment of acute graft vs host disease (AGVHD).
1,2 LPDs occurring after allogeneic stem cell transplant, differ from LPD arising after solid organ transplant, in that LPDs after allogeneic stem cell transplant are usually of donor origin and tend to occur within the first 1.5-6 months following stem cell transplant, whereas LPDs after solid organ transplant tend to occur later and arise from the host (transplant recipient). 1 To date, only two cases of an EBV-associated LPD have been reported to occur after a NMAPBPCT. 3, 4 We present here the case of an EBV-associated B cell LPD of donor origin, arising within 2 months of a matched sibling donor NMAPBPCT in a patient who received fludarabine, cyclophosphamide, and rabbit antithymocyte globulin for the preparative therapy. The unique circumstance of the intense immunosuppression occasioned by the preparative therapy and serologic evidence of recent EBV infection in the donor may have predisposed the recipient to the development of the LPD despite the use of an unmodified stem cell graft.
Case report
A 39-year-old male was diagnosed with CS IIIB peripheral T-cell lymphoma in 11/97 by right cervical lymph node biopsy. He was high risk by IPI score at diagnosis and received CHOP Â 4, followed by cyclophosphamide/total body irradiation and autologous peripheral blood stem cell transplant in 2/98. He remained in CR until 11/00 when a left cervical lymph node biopsy showed a CD30+/Alk+/ CD43+/CD45RO+/CD3-/CD20-anaplastic large cell lymphoma (Figure 1a-d) . He received salvage chemotherapy with ifosfamide, carboplatin and etoposide therapy Â 4 achieving CR, and then underwent NMAPBPCT in 5/01. Conditioning therapy was fludarabine 25 mg/M 2 D-10 to D-6, cyclophosphamide 60 mg/kg day-6 to day-5, and rabbit antithymocyte globulin 2.5 mg/kg day-4 to day-1. Posttransplant immunosuppression was with cyclosporin A (CSA). He received G-CSF mobilized peripheral blood progenitor cells from a 6/6 antigen matched sister. He received 3.95 Â 10 6 CD34+PBPC/kg recipient weight and 3.29 Â 10 8 CD3+cells/kg recipient weight, and achieved ANCX500/ml on day+12 and PltX20 000/ml on day+15. T-cell chimerism studies were done every 2 weeks and the patient remained a mixed T-cell chimera until his death. The patient was admitted on day+33 for persistent culturenegative fevers. Repeated assays for CMV by PCR in the peripheral blood were negative. On admission, total bilirubin and alkaline phosphatase were normal, but rapidly rose to 15 mg/dl and 500 U/l, respectively, after 6 days. Total WBC rose from 4000/ml on admission to 88 000/ml at the time of death. Peripheral white blood cell differential revealed a majority of plasmacytoid lymphs and plasma cells. Bone marrow 1 week prior to admission was normal. Liver biopsy antemortem showed an atypical periportal lymphoid infiltrate of large immunoblastic cells with an admixture of smaller bland lymphocytes (Figure 2 ). Immunohistochemical stains on the liver biopsy showed polyclonal lambda and kappa staining of the periportal infiltrating lymphocytes, with a predominance of lambda staining cells. The immunoblastic appearing cells did not stain for CD3/CD20/CD30 and ALK protein, but did stain positively for CD79a/LCA and CD43. In situ hybridization for EBV RNA (EBER 1) was strongly positive in the periportal infiltrating lymphocytes (Figure 2a and b) . FISH studies for the X and Y chromosomes on the liver biopsy revealed female (XX) tumor cells, while the surrounding normal liver was male (XY) (Figure 3 ). Serum IEF showed three oligoclonal IgG lambda bands, 1 IgM lambda band and 1 IgM kappa band. Immunoglobulin heavy chain gene rearrangement was polyclonal by PCR analysis. CSA was stopped. The patient rapidly developed severe lactic acidosis, oliguric renal failure, and died on day+44. Both patient and donor had positive IgG titers for EBV VCA and EBNA pretransplant. Moreover, the donor also had an elevated IgM titer for EBV VCA in the pretransplant specimen.
Discussion
NMAPBPCT aims to reduce the toxicity of the preparative therapy by decreasing the dose intensity of the therapy, Fatal EBV LPD after nonmyeloablative transplant KW Zamkoff et al while at the same time inducing a sufficient degree of immunosuppression in the recipient to allow for successful engraftment of the transplanted cells. 5 The patient reported in the present work received preparative therapy designed to provide maximum immunosuppression in the recipient with the use of fludarabine, cyclophosphamide, and rabbit antithymocyte globulin. To date, only two other cases of post-transplant EBV-associated LPD after NMAHSCT have been reported in the literature. 3, 4 All three patients now reported in the literature who developed posttransplant EBV-associated LPD after nonmyeloablative preparative therapy, received either antithymocyte globulin or campath 1H as part of their preparative therapy. In two other reported series of patients who underwent nonmyeloablative matched related donor stem cell transplants and who received antithymocyte globulin as part of the preparative therapy, no post-transplant EBV LPD was described. 6, 7 Rabbit antithymocyte globulin when used as part of the preparative therapy in allogeneic stem cell transplants has been shown to persist in the serum for up to 5 weeks post transplant and to inhibit PHA-stimulated Tcell mitogenesis for at least 3 weeks post-transplant. 8, 9 The detection in the pretransplant donor serum of positive titers for both IgM EBV viral capsid antigen (VCA) and IgG EBV VCA would indicate that the donor for our patient had experienced an EBV infection within 1-2 months of the stem cell transplant. 10 Recent infection in the donor would be expected to result in a greater frequency of latent EBVinfected B cells than if the serologically positive donor had not had a recent infection. 11 In healthy individuals, EBV infection does not usually result in EBV-driven LPD. However, in the patient being reported, the simultaneous occurrence of recent donor EBV infection and the administration of potent immunosuppressive therapy in the pretransplant and the post-transplant periods with fludarabine, cyclophosphamide, rabbit antithymocyte globulin and cyclosporin most likely resulted in markedly impaired recipient EBV T cell immunity, and contributed to the development of a post-transplant LPD. The high frequency of prior EBV infection in the normal adult stem cell donor population and the rarity of post-nonmyeloablative EBV LPD, would suggest that residual EBV T-cell immunity persists after most NMAPBPCT. However, our data, in conjunction with the other two reported cases, suggest that the use of antilymphocyte antiserum in the preparative therapy for a nonmyeloablative stem cell transplant may increase the risk of developing a posttransplant EBV-associated LPD. Moreover, if the donor has evidence of a recent EBV infection, as in the present case, delaying the transplant until there is loss of donor IgM to EBV VCA would seem prudent. If the transplant cannot be delayed, then a strategy of frequent monitoring of EBV-DNA load in the peripheral blood of the recipient post-transplant should be undertaken. In this way, one can begin to look at the effect of positive IgG and/or IgM EBV titers in the donors, and determine prospectively if recent EBV infection in the donor plays a significant role in the development of post-transplant LPD. A strategy of preemptive therapy with anti-CD20 monoclonal antibody based on rising titers of EBV-DNA has recently been shown to reduce both the incidence and mortality from EBV-associated LPD post allogeneic stem cell transplant. 12 This approach should be undertaken in nonmyeloablative stem cell transplants from EBV sero-positive donors, especially in those recipients receiving either antithymocyte globulin or campath 1-H as part of the preparative therapy.
